The inotropic effects of UK 14,275, a phosphodiesterase inhibitor, in man.
1. UK 14,275 (Pfizer) an inotropic agent with cardiac phosphodiesterase inhibitory activity, was administered to ten healthy male volunteers. 2. The inotropic activity was assessed by non-invasive measurement of systolic time intervals (STI). 3. The compound had significant inotropic activity in the doses administered, as judged by the shortening of pre-ejection period (PEP), without any significant chronotropic activity. 4. The inotropic effect was abolished when measurements were repeated following beta-adrenoceptor blockade with oral propranolol. 5. The inotropic activity was compared to that of intravenous isoprenaline.
D000328:Adult; D004347:Drug Interactions; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology*; D013268:Stimulation, Chemical
D010726:Phosphodiesterase Inhibitors; D010880:Piperidines; D011799:Quinazolines; D011433:Propranolol; C012675:buquineran; D007545:Isoproterenol